GlobeNewswire

Galapagos reports positive topline results with GLPG1205 in IPF patients in PINTA Proof-of-Concept trial

Share
  • Placebo-adjusted improvement in forced vital capacity (FVC) decline of 42mL across treatment groups at 26 weeks
  • Correlation between FVC decline and pulmonary lobar volume change observed, as measured by functional respiratory imaging (FRI)
  • GLPG1205 planned to progress to dose finding Phase 2b study

Mechelen, Belgium; 30 November 2020, 22.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) announces positive topline results with its investigational GPR84 antagonist GLPG1205 in Proof-of-Concept Phase 2 trial in idiopathic pulmonary fibrosis (IPF) patients.

The PINTA trial was a randomized, double-blind, placebo-controlled trial investigating a 100mg once-daily oral dose of GLPG1205. The study recruited and included a total of 68 IPF patients. Participants were administered drug candidate or placebo (2:1 randomization) for 26 weeks and could remain on their standard of care as background therapy, i.e. nintedanib, pirfenidone or neither. The primary objective of the trial was to assess the change from baseline in FVC (in mL) over 26 weeks compared to placebo. Other measures included safety, tolerability, time to major events, changes in functional exercise capacity, quality of life, pharmacokinetics, pharmacodynamics and FRI.

At week 26, patients receiving GLPG1205 on top of standard of care showed a smaller FVC decline, with a difference of 42mL versus placebo on top of standard of care (-76mL on placebo; -34mL on treatment). The study was not powered to show statistical significance. The FVC trend was consistent across the three treatment strata. In addition, the change in pulmonary lobar volume, as measured by FRI, correlates with the FVC decline observed.

No relevant safety signals were observed for GLPG1205 alone and on top of pirfenidone. The most frequently reported adverse events on GLPG1205 alone were gastrointestinal disorders, especially nausea. In the treatment arm of GLPG1205 on top of nintedanib, a higher rate of early discontinuations and high grade TEAEs were observed. In the arm of the study with GPLG1205 on top of nintedanib, there was one death due to an exacerbation of IPF, which was determined to be unrelated to study treatment.

Based on the results of this trial, Galapagos plans to progress GLPG1205 in a dose finding Phase 2b trial.

The full results of the PINTA trial will be submitted to a future medical conference and peer-reviewed medical journals.

“Keeping in mind the limitations of this early clinical study, the PINTA study with GLPG1205 is a positive trial. The consistent changes observed across treatment strata, using different analytical methods, including FRI, are very encouraging. While we need to understand more about long-term tolerability of the drug, the PINTA results warrant further investigation,” said Prof. Dr. Toby Maher, Professor of Medicine at Keck School of Medicine, University of Southern California.

“We wish to thank participating patients and physicians in the PINTA trial. We are pleased to see a second novel mechanism of action from our innovative platform show early signs of activity in IPF, a highly fatal disease for which improved therapies are desperately needed. This additional novel mode of action may complement the anti-fibrotic approaches within our expanding IPF portfolio,” said Dr. Piet Wigerinck, Chief Scientific Officer of Galapagos.

About GLPG1205 and the fibrosis portfolio
GLPG1205 is a small molecule selectively functionally antagonizing GPR84. Galapagos identified the GPR84 target using its proprietary target discovery platform. GLPG1205 showed promising results in relevant pre-clinical models for IPF. Galapagos currently has several drug candidates with distinct mechanisms of action in its portfolio aimed at building a fibrosis franchise, including ziritaxestat (GLPG1690, autotaxin inhibitor) in the ISABELA Phase 3 program in IPF, ziritaxestat in the NOVESA Phase 2 trial in systemic sclerosis, GLPG1205, GLPG4716 (chitinase receptor inhibitor) preparing for Phase 2 in IPF, and GLPG4124 and GLPG4586, currently in pre-clinical development. 

GLPG1205 is investigational; its efficacy and safety have not been evaluated by any regulatory authority.
Information about studies with GLPG1205: www.clinicaltrials.gov
For more information about GLPG1205: www.glpg.com/ipf

About IPF

IPF is a chronic, relentlessly progressive fibrotic disorder of the lungs that typically affects adults over the age of 40. There are approximately 200,000 patients with IPF in the U.S. and Europe. As such, IPF is considered a rare disease. The clinical prognosis of patients with IPF is poor as the median survival at diagnosis is around 3 years. Currently, no medical therapies have been found to cure IPF. The medical treatment strategy aims to slow the disease progression and improve the quality of life.

About Galapagos

Galapagos (Euronext & NASDAQ: GLPG) discovers and develops small molecule medicines with novel modes of action, several of which show promising patient results and are currently in late-stage development in multiple diseases. The company’s pipeline comprises early discovery through to Phase 3 programs in inflammation, fibrosis, and other indications. Galapagos’ ambition is to become a leading global biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines. More information at www.glpg.com.

Contact

Investors:
Elizabeth Goodwin
VP Investor Relations
+1 781 460 1784

Sofie Van Gijsel
Senior Director Investor Relations
+32 485 19 14 15
ir@glpg.com

Media:
Carmen Vroonen
Global Head of Communications & Public Affairs
+32 473 824 874

Anna Gibbins
Senior Director Therapeutic Areas Communications
+44 7717 801900

communications@glpg.com

Forward-looking statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those referred to in the forward-looking statements and, therefore, the reader should not place undue reliance on them. These risks, uncertainties and other factors include, without limitation, the risk that ongoing and future clinical studies with GLPG1205 and other drug candidates from Galapagos’ fibrosis portfolio may not be completed in the currently envisaged timelines or at all, the inherent uncertainties associated with competitive developments, clinical trial and product development activities and regulatory approval requirements (including that data from the ongoing and planned clinical research programs may not support registration or further development of GLPG1205 and other drug candidates from Galapagos’ fibrosis portfolio due to safety, efficacy or other reasons), Galapagos' reliance on collaborations with third parties and that Galapagos’ estimations regarding its GLPG1205 and fibrosis portfolio development program and regarding the commercial potential of GLPG1205 and of other drug candidates from Galapagos’ fibrosis portfolio, may be incorrect, as well as those risks and uncertainties identified in our Annual Report on Form 20-F for the year ended 31 December 2019 and our subsequent filings with the SEC. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The forward-looking statements contained herein are based on management’s current expectations and beliefs and speak only as of the date hereof, and Galapagos makes no commitment to update or publicly release any revisions to forward-looking statements in order to reflect new information or subsequent events, circumstances or changes in expectations.

Attachment


About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

SEK TENDER OPERATION ANNOUNCEMENT FOR ONWARD LENDING27.1.2021 16:20:00 CETPress release

Bid date, 2021-01-29Bid Submission Date2021-01-29Bid times10.30-11.00 (CET/CEST) on the Bid dateOffered Amount50 billion SEKMaximum Permitted Bid Volume12.5 billion SEK from an individual bidderSettlement Date2021-02-02Minimum Permitted Bid Volume10 million SEK per bidFinal Repayment Date2025-02-03Maximum Allocation25 per cent of Offered AmountAllocation TimeNot later than 11.30 (CET/CEST) on the Bid dateRepayment Date2022-02-02Option Repayment Date 12023-02-02Option Repayment Date 22024-02-02Interest rateThe Riksbank´s applicable repo rateAdditional interest rate0.10 per centConfirmation of bids to e-maileol@riksbank.se Stockholm, 2021-01-27 This is a translation of the special terms and conditions published on www.riksbank.se. In the case of any inconsistency between the English translation and the Swedish language version, the Swedish language version shall prevail. Complete terms and conditions can be retrieved at www.riksbank.se.

Hexagon Purus selected by Talgo for first zero-emission hydrogen train in Spain27.1.2021 16:00:00 CETPress release

Hexagon Purus has received an order to deliver high pressure cylinders to Talgo, S.A., a leading manufacturer of intercity, standard and high speed passenger trains, for its first hydrogen prototype train. The Talgo Vittal-One train will be built and deployed in Spain and will serve as a testbed for how hydrogen technologies could be implemented in the Iberian Southwest. “There are more than 10,000 diesel trains in operation across Europe that will need to be replaced over the next 15 years. For distances between 400-800 km, hydrogen-powered trains are a smart solution to reduce local emissions without incurring the high cost of electrifying the tracks,” says Michael Kleschinski, Executive Vice President of Hexagon Purus. “We are excited to help develop the solutions needed for this ground-breaking move in public transit.” “Green hydrogen is no longer the future, it is a reality,” says Mr. Emilio García. Innovation Director at TALGO. “The start-up of hydrogen trains such as Talgo’s Vit

Property Carriers Beat Fraud with New Prior Loss Images in Verisk’s ISO ClaimSearch®27.1.2021 15:45:00 CETPress release

Jersey City, N.J., Jan. 27, 2021 (GLOBE NEWSWIRE) -- Verisk (Nasdaq:VRSK) announced that ISO ClaimSearch, the world’s largest database of property and casualty insurance (P&C) claims, has enhanced its robust claim intelligence platform by adding prior loss image matching. This automates previously laborious processes and significantly bolsters fraud protection. Millions of property images have been added to the system, which contains over 1.5 billion claim records and receives ongoing contributions from more than 90% of P&C insurers. Verisk created this enhancement – available at no cost to participants -- by tapping into participant-authorized claim images from its Xactware property estimation system. How ISO ClaimSearch works: As adjusters review ISO ClaimSearch match reports, a simple on-screen camera icon easily identifies prior claims containing photos.Prior loss images may reveal pre-existing damage, or the same damage being claimed again.Image forensics expose anomalies such as

Virgin Hyperloop Unveils Passenger Experience Vision27.1.2021 15:00:00 CETPress release

Groundbreaking design shows end-to-end passenger experience for the 21st century LOS ANGELES, Jan. 27, 2021 (GLOBE NEWSWIRE) -- Just months after their first passenger testing, Virgin Hyperloop today unveiled its vision for the future hyperloop experience. The newly-released concept video takes the viewer step-by-step through a hyperloop journey, from arriving at the portal to boarding the pod. “Showing the passenger experience of Virgin Hyperloop is a glimpse of the future, following the success three months ago when people rode in a hyperloop pod for the first time,” said Sultan Bin Sulayem, Chairman of Virgin Hyperloop and Group Chairman and CEO of DP World. “We have demonstrated the maturity of our technology. We are getting closer to commercialization of what will be the first new mass-scale transportation mode in a century.” “Designing a new mode of transportation from scratch is both an opportunity and a responsibility,” said Sara Luchian, Virgin Hyperloop’s Director of Passenge

Virgin Hyperloop Unveils Passenger Experience Vision27.1.2021 15:00:00 CETPress release

Groundbreaking design shows end-to-end passenger experience for the 21st century LOS ANGELES, Jan. 27, 2021 (GLOBE NEWSWIRE) -- Just months after their first passenger testing, Virgin Hyperloop today unveiled its vision for the future hyperloop experience. The newly-released concept video takes the viewer step-by-step through a hyperloop journey, from arriving at the portal to boarding the pod. “Showing the passenger experience of Virgin Hyperloop is a glimpse of the future, following the success three months ago when people rode in a hyperloop pod for the first time,” said Sultan Bin Sulayem, Chairman of Virgin Hyperloop and Group Chairman and CEO of DP World. “We have demonstrated the maturity of our technology. We are getting closer to commercialization of what will be the first new mass-scale transportation mode in a century.” “Designing a new mode of transportation from scratch is both an opportunity and a responsibility,” said Sara Luchian, Virgin Hyperloop’s Director of Passenge

Golar LNG Partners LP Cash Distributions27.1.2021 15:00:00 CETPress release

Golar LNG Partners LP (“the Partnership”) (NASDAQ: GMLP) announced today that its board of directors has approved a quarterly cash distribution with respect to the quarter ended December 31, 2020 of $0.0202 per common and general partner unit. This cash distribution will be paid on February 12, 2021 to all common and general partner unitholders of record as of the close of business on February 5, 2021. As set forth in our press release dated January 13, 2021, the Partnership has entered into a merger agreement with New Fortress Energy, Inc. (“NFE”). For additional information, please see the Partnership’s definitive proxy statement which will be filed with the Securities and Exchange Commission. A cash distribution of $0.546875 per Series A preferred unit (NASDAQ: GMLPP) for the period from November 15, 2020 through February 14, 2021 has also been declared. This will be payable on February 15, 2021 to all Series A preferred unitholders of record as at February 8, 2021. Under the merger